We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Physiomics Plc | LSE:PYC | London | Ordinary Share | GB00BDR6W943 | ORD 0.4P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -0.05 | -6.25% | 0.75 | 2,277,502 | 13:43:50 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 0.70 | 0.80 | 0.80 | 0.75 | 0.80 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 543k | -609k | -0.0030 | -2.50 | 1.63M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 14:32:04 | O | 32,933 | 0.747 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 12/12/2024 | 12:00 | UK RNS | Physiomics PLC Contract Award |
| 05/12/2024 | 19:52 | ALNC |  EARNINGS AND TRADING: Synectics deal wins; TruFin to beat expectations |
| 05/12/2024 | 07:52 | ALNC | *Physiomics says new contract will inform treatment of novel cancer.. |
| 05/12/2024 | 07:00 | UK RNS | Physiomics PLC Contract Award |
| 19/11/2024 | 16:50 | UK RNS | Physiomics PLC Result of AGM |
| 08/11/2024 | 07:00 | UK RNS | Physiomics PLC Director Dealing |
| 04/11/2024 | 07:00 | UK RNS | Physiomics PLC Senior Management Announcement |
| 17/10/2024 | 06:00 | UK RNS | Physiomics PLC Notice of AGM |
| 17/10/2024 | 06:00 | UK RNS | Physiomics PLC Contract Award |
| 15/10/2024 | 10:57 | UK RNS | Physiomics PLC IMC Presentation on Company Website - Amendment |
Physiomics (PYC) Share Charts1 Year Physiomics Chart |
|
1 Month Physiomics Chart |
Intraday Physiomics Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 14/12/2024 | 09:59 | Physiomics - Cancer Treatment tech firm working with Merck + Oxford Uni | 11,629 |
| 17/6/2021 | 06:23 | PHYSIOMICS plc Virtual Tumor platform | 4,957 |
| 28/3/2021 | 21:05 | Physiomics PYC 2021 DISCUSSION (MODERATED) | 5 |
| 22/12/2020 | 11:36 | 3 Years ago today | 2 |
| 29/11/2020 | 14:53 | 3 Years ago today | - |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 14:32:05 | 0.75 | 32,933 | 246.01 | O |
| 14:18:09 | 0.72 | 507,614 | 3,629.44 | O |
| 14:12:06 | 0.72 | 80,000 | 576.80 | O |
| 13:55:25 | 0.78 | 145,483 | 1,127.49 | O |
| 13:45:16 | 0.75 | 150,000 | 1,125.00 | O |
| Top Posts |
|---|
Posted at 14/12/2024 09:59 by ravenrussia £20 Million MCAP suggestion is peanuts. More like £200 Million for starters in our space, when you read the PWC's dealmaker report on our sector.. It makes for interesting reading. See below for a summary of why PYC is so under valued:1. Dealmakers in pharmaceuticals and life sciences and in healthcare services are eager to get deals done. 2. Competition for truly innovative assets remains intense. 3. Large pharmaceutical companies will continue to pursue biotech targets and products that can offset revenue declines from lost exclusivity in the coming years. 4. Companies seeking opportunities to digitalise through implementation of analytics technology, digital direct-to-consumer therapeutics offerings, smart health devices and other software innovations will continue to acquire or partner with data and analytics and other technology companies that can deliver these digital solutions. For example: 5. Merck: Acquired Harpoon Therapeutics for an estimated $680 million 6. Novartis: Acquired Calypso Biotech for $250 million 7. Aditxt: Acquired Evofem Biosciences for $100 million 8. There were 420 M&A deals in our sector globally in Q3 2024, worth a total value of $32.4bn. Source: GlobalData’s Deals Database. 9. The $3.2bn acquisition of Morphic Holdings by Eli Lilly and Co was the industry’s largest disclosed deal in Q3 2024. 10. Interestingly for PYC investors AI / State of the art virtual technology accounted for 11 pharmaceutical deals announced in Q3 2024, worth a total value of $1.7bn. The $1.1bn acquisition of Integrated Oncology Network by Cardinal Health was the industry’s largest disclosed deal. hxxps://www.pwc.com/ |
Posted at 14/12/2024 00:14 by ravenrussia TmkYou seem desperate to focus on PYC..you seem to post on nothing else Very unusual |
Posted at 13/12/2024 16:12 by thiopia Anybody can post on whatever shares they want. Why are you so defensive and concerned about the weak PYC investment case ? |
Posted at 13/12/2024 14:03 by ravenrussia PYC have just won 2 contracts this weekWhy do you keep involving yourself here when you hold no investment ? |
Posted at 13/12/2024 07:49 by tees maar khan The share price is meandering sideways since early July. It had a little spike towards the beginning of August? but to no avail. There's been no real signs of any progress even from a TA perspective.TMK |
Posted at 08/12/2024 18:37 by ravenrussia Hello CbeadleThanks for that, I will look into thar I have spoken to the Ceo at PYC twice now and I am very impressed I was also at the AGM and they are very excited about the relationship with DoseMe RX |
Posted at 08/12/2024 17:24 by ravenrussia PYC hit record contracts won year end June 2024 and have record revenues booked for June to Dec 2024financial year ending 30 June 2024 resulted in a record year for the total value of new contracts won (more than £1.1m), a peak unweighted pipeline value of more than £1.7m and a record level (based on last six years of data) of contracted revenue to be taken forward into the following year (more than £500k). |
Posted at 01/10/2024 17:23 by davevt This share has consistently dropped from 10p down to what it is now, year after year with increased turnover...so turnover has nothing to do with share price. |
Posted at 01/10/2024 11:43 by davevt Raven, right, so it's currently priced into the current share price, as it's foreknowledge. |
Posted at 30/9/2024 16:19 by davevt Raven, so if we already know the expected turnover is going to be 1.7m, that's now priced into the share price, as it's public knowledge. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
